Currently, four types of drugs are recommended for the purposes of treating HF with a reduced ejection fraction (HFrEF) in order to reduce the risk of hospitalization and death (with a level of evidence IA): angiotensin-converting enzyme (ACE) inhibitors; beta-blockers; mineralocorticoid antagonists; and SGLT2i. This evidence concerns the gene ACE and hydrops fetalis.